| Date | Title | Description |
| 28.08.2026 | BioCryst is profitable. Now it wants to buy more rare disease drugs | BioCryst expects up to $645 million in 2026 sales from its HAE drug Orladeyo, giving it capital to pursue external deals.
As large drugmakers prioritize multibillion dollar assets, small and midsize biotech companies are increasingly steppi... |
| 29.06.2026 | Lycia Therapeutics Raises $75M in Series D Funding | Lycia Therapeutics, a South San Francisco, California-based developer of extracellular protein degradation and lysosomal targeting chimera (LYTAC) therapeutics, raised $75m in Series D funding.
The round was co-led by Janus Henderson Invest... |
| 29.06.2026 | Alebund Pharmaceuticals (09637.HK) Debuts on the HKEx Main Board | Deepening Its Commitment to Kidney Disease and Accelerating Toward Becoming a Global Leader in Renal Innovation
SHANGHAI, June 29, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"... |
| 29.06.2026 | Alpha-1 Antitrypsin Gene Editing Startup Raises $230 Million: Serapha Bio AATD Debut | By Shannon Harwood
Published: Jun 29 2026, 10:37 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 29.06.2026 | Lycia Therapeutics Raises $75 Million Series D To Advance LYTAC Pipeline | Lycia Therapeutics announced that it has completed an oversubscribed $75 million Series D financing. The financing was co-led by existing investor Janus Henderson Investors and new investor Balyasny Asset Management. The round also included... |
| 14.05.2026 | METiS TechBio, the World's First Publicly Listed AI-Powered Drug Delivery Company, Debuts on the Hong Kong Stock Exchange, "The SpaceX of Pharmaceuticals" Ushers in a New Era of Biopharmaceu... | HONG KONG, May 14, 2026 /PRNewswire/ -- METiS TechBio (7666.HK), a tech-bio company focused on AI-powered nanodelivery innovation, today successfully listed on the Hong Kong Stock Exchange (HKEX), becoming the world's first publicly listed ... |
| 06.05.2026 | Windward Bio Announces $165 Million Crossover Financing To Advance Long-Acting Immunology Pipeline | Windward Bio, a private, clinical-stage biotechnology company based in Basel, Switzerland, has announced an upsized $165 million crossover financing led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, S... |
| 05.05.2026 | Windward Bio secures USD 165 million to advance clinical trials |
WIN378, Windward's lead program, is a next-generation, fully human monoclonal antibody that potently binds to the thymic stromal lymphopoietin (TSLP) ligand. This well-validated cytokine plays a key role in the development and progression ... |
| 25.02.2026 | NYU Abu Dhabi and RTW Investments Announce Strategic Collaboration to Advance Healthcare and Life Sciences Innovation | NYU Abu Dhabi and RTW Investments, LP (“RTW”) today announced a strategic collaboration to advance executive education, thought leadership, and cross-sector engagement in healthcare, biotechnology, and life sciences across the region.
The c... |
| 20.01.2025 | Umoja Biopharma's $100 Million Leap: A New Era for In Vivo CAR T Cell Therapies | Umoja Biopharma is on the rise. The Seattle-based company has just secured $100 million in Series C financing. This is not just a number; it’s a statement. It signals a bold step forward in the world of biotechnology. The funding round was ... |
| 20.01.2025 | Umoja Biopharma Raises $100M in Series C Financing | Umoja Biopharma, a Seattle, WA-based clinical-stage company which specializes in vivo cell therapies, raised $100M Series C financing.
The round was led by Double Point Ventures and DCVC Bio, with participation from new and existing investo... |
| 14.01.2025 | Windward Bio: Charting New Waters in Immunology with $200 Million Series A Financing | In the vast ocean of biopharmaceutical innovation, Windward Bio has set sail with a robust $200 million Series A financing. This private, clinical-stage company aims to navigate the turbulent waters of immunological diseases, focusing on se... |
| 13.01.2025 | Windward Bio launches with $200 million Series A financing round |
Windward Bio’s lead candidate, WIN378, which has been in-licensed from Kelun-Biotech and Harbour BioMed, is a potential best-in-class, long-acting monoclonal antibody targeting the ligand of thymic stromal lymphopoietin (TSLP) that has the... |
| 10.01.2025 | Numab Therapeutics: A Financial Surge in the Fight Against Cancer | In the world of biotechnology, where innovation meets investment, Numab Therapeutics has made headlines with its recent financial maneuvering. The Swiss company, known for its pioneering work in multi-specific antibodies, has successfully c... |
| 09.01.2025 | Numab raises additional CHF50 million |
In 2024 Numab caused a stir with the acquisition of the biotech’s spin-out Yellow Jersey Therapeutics by Johnson & Johnson for $1.25 billion. Numab’s immuno-oncology therapeutic NM26 entered the clinic and the company started a collabo... |
| 20.12.2024 | Ottimo Pharma: A New Dawn in Cancer Treatment with $140 Million Boost | In the world of biotechnology, every dollar counts. Ottimo Pharma, a New York City-based biotech firm, has just raised over $140 million in a Series A funding round. This infusion of capital is not just a financial milestone; it’s a beacon ... |
| 20.12.2024 | Ottimo Pharma: Over $140 Million (Series A) Raised To Advance Bifunctional Medicines | Ottimo Pharma – a private biotech company pioneering bifunctional medicines to extend the lives of people with cancer – announced the completion of a Series A financing round of over $140 million. The funding round was led by OrbiMed, Avoro... |
| 15.11.2024 | The Surge of Innovation: Beta Bionics and PMWeb Secure Major Investments | In the fast-paced world of technology and healthcare, two companies have recently made headlines by securing significant funding. Beta Bionics and PMWeb are not just raising capital; they are paving the way for transformative solutions in d... |
| 15.11.2024 | Beta Bionics Closes $60M Series E Financing | Beta Bionics, an Irvine, CA-based company which specializes in the development of advanced diabetes management solutions, raised $60M in Series E funding.
The round was led by Wellington Management. Previous investors Eventide Asset Managem... |
| 09.11.2024 | Evommune Secures $115 Million to Tackle Chronic Inflammatory Diseases | In the bustling world of biotechnology, Evommune has made waves. The Palo Alto-based company recently secured $115 million in Series C financing. This funding is a lifeline, aimed at advancing their clinical-stage pipeline focused on immune... |
| 08.11.2024 | Evommune: $115 Million (Series C) Secured To Advance Clinical-Stage Pipeline Addressing Chronic Inflammatory Diseases | Evommune – a clinical-stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases – announced the completion of a $115 million Series C financing. The funding was co-led by new investors RA... |
| 30.10.2024 | GlycoMimetics To Acquire Crescent Biopharma | GlycoMimetics (NASDAQ: GLYC), a Rockville, MD-based late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, acquired Crescent Biopharma, Inc., a biotechnology company advancing a pipeli... |
| 24.10.2024 | Jade Biosciences Extends Financing; Total To $95M | Jade Biosciences, a Vancouver, BC, Canada-based biotechnology company dedicated to developing therapies for patients living with autoimmune diseases, extended its financing, bringing the total raised to $95M.
The round added Frazier Life Sc... |
| 07.10.2024 | Kailera Therapeutics: $400 Million (Series A) Raised To Advance Next-Gen Therapies For Obesity | Kailera Therapeutics announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for treating obesity and related conditions. And Kailera launches with a $400 million... |
| 01.10.2024 | Aktis Oncology: $175 Million (Series B) Secured To Develop Targeted Alpha Radiopharmaceuticals For Treating Tumors | Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, announced the successful closing of an oversubscribed and u... |
| 30.09.2024 | Aktis Oncology Raises $175M in Series B Funding | Aktis Oncology, a Boston, MA-based clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, closed a $175m Series B financing.
The rou... |
| 28.05.2024 | Johnson & Johnson acquires Numab spin-off for USD 1.25 billion |
Numab Therapeutics AG based in Horgen (ZH) is developing multi-specific antibody-based immunotherapies for inflammation and cancer. Johnson & Johnson will acquire global rights to Numabs lead molecule NM26, a Phase 2-ready investigatio... |
| 28.02.2023 | Oricell Closes $45M Series B1 Financing to Expand Development of Key Products | SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Oricell Therapeutics Co., Ltd ("Oricell" or "the Company"), a China-based innovative pharmaceutical company committed to the development of tumor cellular immunotherapeutics, today... |
| 20.05.2021 | Numab Therapeutics Completes CHF 100 Million Series C Financing | |
| 20.05.2021 | Numab Therapeutics Completes CHF 100 Million Series C Financing | Numab Therapeutics aims to write the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. Its lead product was designed to balance potent anti-tumor immunity wit... |
